All In Biotech

Drug Trial Radar · NCT04854707

An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data

An Observational Study "FOLLITROPIN" Comparing the Efficacy of Follitropin Alpha Biosimilar: the Real-world Data

Last checked: Nov 19, 2026Latest source record: Oct 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

5,484

Actual

Start

Jan 12, 2020

Primary completion

Dec 20, 2020

Study completion Jan 20, 2021

Sponsor

Lead sponsor
IVFarma LLCIndustry
Sponsor type
Industry
Collaborators
Institute for Preventive and Social Medicine
First posted
Apr 22, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 43 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Aim to investigate the efficacy of follitropin alpha biosimilar therapy (Primapur®) in nonselected real-world population.

Conditions

  • Reproductive Issues
  • Reproductive Disorder
  • Fertility Disorders
  • Fertility Issues
  • Gynecologic Disease
  • IVF

Interventions

  • Follitropin AlfaDrug

    Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.

  • Follicle Stimulating Hormone/Luteinizing HormoneDrug

    Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.

  • Follitropin AlfaDrug

    Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.

  • Follitropin AlfaDrug

    Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.

  • Follicle Stimulating Hormone/Luteinizing HormoneDrug

    Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Oocytes RetrievedTime frame: From date of start of ovarian stimulation with follitropin alpha up to 15 days
  2. Percentage of Participants With Ongoing Clinical Pregnancy Per Embryo TransferTime frame: At least 6 weeks after embryo transfer

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Center for reproductive medicine, Barnaul

    Barnaul, Russia

  • Center for reproductive medicine, Irkutsk

    Irkutsk, Russia

  • Clinic "Mother and Child" Kazan

    Kazan', Russia

  • Clinic "Mother and Child" Kostroma

    Kostroma, Russia

  • Clinic "Mother and Child" Krasnodar

    Krasnodar, Russia

  • Center for reproductive medicine, Krasnoyarsk

    Krasnoyarsk, Russia

  • AltraVita IVF clinic

    Moscow, Russia

  • Center of Reproductive Medicine and Genetics "Nova Clinic"

    Moscow, Russia

  • Clinic "Mather and Child" Lefortovo

    Moscow, Russia

  • Clinic "Mather and Child" Savelovskaya

    Moscow, Russia

  • Clinic "Mother and Child" Khodynskoe Pole

    Moscow, Russia

  • Clinic "Mother and Child" Kuntsevo

    Moscow, Russia

  • Clinic "Mother and Child" South-West

    Moscow, Russia

  • Clinical Hospital MD GROUP (Perinatal Center on Sevastopolskiy)

    Moscow, Russia

  • Clinical Hospital Lapino

    Moscow Oblast, Russia

  • Clinic "Mother and Child"

    Nizhny Novgorod, Russia

  • Medika-2

    Novokuznetsk, Russia

  • Center for reproductive medicine, Novosibirsk

    Novosibirsk, Russia

  • Clinical Hospital "Avicenna"

    Novosibirsk, Russia

  • Ceter for reproductive medicine, Omsk

    Omsk, Russia

  • Clinic "Mother and Child" Perm

    Perm, Russia

  • Clinic "Mother and Child" Rostov-on-Don

    Rostov-on-Don, Russia

  • Clinic "Mather and Child"

    Ryazan, Russia

  • "Genesis" Reproduction Centre

    Saint Petersburg, Russia

  • Clinic "Mother and Child" Saint-Petersburg

    Saint Petersburg, Russia

  • Clinical Hospital "Mother and Child"

    Samara, Russia

  • Clinic "Mather and Child" Tula

    Tula, Russia

  • Clinical Hospital "Mother and Child"

    Tyumen, Russia

  • Clinical Hospital "Mother and Child"

    Ufa, Russia

  • Clinic "Mother and Child" Vladimir

    Vladimir, Russia

  • Clinic "Mather and Child" Vladivostok

    Vladivostok, Russia

  • Clinic "Mother and Child" Volgograd

    Volgograd, Russia

  • Clinic "Mother and Child" Voronezh

    Voronezh, Russia

  • Clinic "Mother and Child" Yaroslavl

    Yaroslavl, Russia

  • Clinical Institute of Reproductive Medicine

    Yekaterinburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.